<DOC>
	<DOCNO>NCT00810706</DOCNO>
	<brief_summary>The ATENA phase III randomize parallel-group multicenter trial design compare 5 year adjuvant exemestane versus 5 year observation postmenopausal woman operable breast cancer receive 5-7 year adjuvant tamoxifen . The primary endpoint core protocol disease-free survival ( DFS ) . Exemestane treatment plan 5 year unless disease relapse excessive toxicity document , patient refuse treatment new anti-cancer therapy initiate .</brief_summary>
	<brief_title>Adjuvant Post-Tamoxifen Exemestane Trial</brief_title>
	<detailed_description>- Patients must complete least 5 year 7 year continue treatment tamoxifen ( 20 mg/day ) , tamoxifen could discontinue 6 month prior study entry . - A substudy ( ATENA lipid substudy ) design evaluate change patient ' serum lipid profile study treatment .</detailed_description>
	<mesh_term>Breast Neoplasms</mesh_term>
	<mesh_term>Exemestane</mesh_term>
	<mesh_term>Tamoxifen</mesh_term>
	<criteria>postmenopausal woman histologically confirm stage IIIIA primary adenocarcinoma breast estrogen and/or progesterone receptor positive unknown patient undergone surgery curative intent patient must complete least 5 year 7 year continue treatment tamoxifen ( 20 mg/day ) , tamoxifen could discontinue 6 month prior study entry Absence evidence local distant metastatic disease require prior randomization DCIS , bilateral breast cancer , evidence metastasis , ER Pgr negative</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>80 Years</maximum_age>
	<verification_date>December 2008</verification_date>
	<keyword>Breast Cancer</keyword>
	<keyword>Aromatase inhibitor</keyword>
	<keyword>Exemestane</keyword>
	<keyword>Tamoxifen</keyword>
	<keyword>Lipids</keyword>
</DOC>